Mumbai, April 10, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg. It is indicated in the treatment of:
Adults: Efficacy was established in one 5-week trial, three 6-week trials, and one maintenance study Pediatrics: Efficacy was established in two 8- to 9-week trials of patients 8 to 18 years of age
Adults: Efficacy was established in two 13-week trials
Pediatrics: Efficacy was established in one 13-week trial in pediatric patients 7 to 17 years of age
Adults: Efficacy was established in two 8-week trials and one 16-week trial
Adults: Efficacy was established in two 12-week trials
Fluoxetine Tablets, 60mg, had annual sales of approximately USD 41 million in the US (IQVIA MAT February 2019).
Corporate Comm India(CCI Newswire)
New Delhi, January 10, 2025: Arya Vaidya Pharmacy (Coimbatore) Ltd. (AVP), a pioneer in Ayurvedic healthcare…
By Srinath Rao, Senior Vice President, CitiusTech A few decades back, the purpose of watches…
Pharmapack Europe: 'Basel the best location for drug device innovation in Europe thanks to combination…
New Delhi, January 07, 2025: HMP virus can travel to the brain, or it can…
~ Co-authored by Dr Sanjith Saseedharan, Director-Critical Care, S. L. Raheja Hospital- A Fortis Associate…
Patients Embrace Flexibility with 37% of Online Doctor Consultations now happening even After 6 PM,…